The FTSE 100’s still falling! Could this dividend stock help mend your stocks portfolio?

Royston Wild discusses a top FTSE 100 dividend share that might bounce back soon.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

These are stressful times to be a share investor. The FTSE 100 continues to dive and a fall below 6,500 points earlier took it to its lowest since summer 2016.

It’s true that those with a sound stock-buying strategy should have little to fear in the wider scheme of things. You should always look to load up with a view to holding companies for the long term, say a minimum of 10 years. If you’ve done your homework then, it’s likely that your equities will recover from the current rout and make you some big profits in the coming years.

Still, it’s quite disconcerting for someone to see their stocks portfolio smeared in red. With the global issues continuing, it’s difficult to predict when the haemorrhaging will stop. In times like this it may be a good idea to load up on classic defensive stocks.

The current washout is hammering all stocks, regardless of their risk profiles. But safe havens could be among the first to rise when market appetite tentatively begins to pick up.

A safe-haven sinker

Healthcare is a classic safe haven in times of social, political and economic crises like now. Consumer spending on a variety of goods and services might take a whack, but one thing we cannot do without is medicines.

I believe that buying shares in GlaxoSmithKline (LSE: GSK) could be a good idea following recent heavy selling. The Footsie firm’s fallen 15% in value since hitting 20-year highs in the middle of January. Some insipid full-year financials at the start of the month set the train in motion. And those fears over the COVID-19 crisis have worsened the rout.

At current prices though, Glaxo carries the sort of valuations that could tempt dip buyers before long. Its forward P/E ratio of 13.7 times certainly looks cheap. And a 5.1% dividend yield for 2020 looks juicy too. It beats the corresponding prospective average for the broader FTSE 100 by around one whole percentage point.

Bad news

As I say, those latest financials weren’t exactly top-drawer stuff. Glaxo said that total revenues rose 9% in the fourth quarter to £8.9bn and that adjusted operating profits tanked 16% to £1.9bn. The latter figure in particular was much weaker than the City had been expecting.

This wasn’t the worst of it. Glaxo warned that adjusted earnings per share would likely fall between 1% and 4% at constant exchange rates in 2020. This reflects a ramping-up of R&D costs as well as expectations of more currency-related headwinds.

A long-term lovely

The release was disappointing, sure. But is it a game-changer for Glaxo’s investment case? Certainly not, at least in my opinion.

There were certainly some positive nuggets of information in that latest statement that underlined the pharma play’s terrific long-term profits outlook. Sales of blockbuster new products like Shingrix continued to rip higher in the last quarter. There was exciting news on the pipeline too. Glaxo said that it expects regulatory approval on six products spanning the business in 2020. It is also expecting proof-of-concept readouts on what it deems “several key pipeline assets” in oncology and vaccines later this year.

Its share price might be on the defensive today. But I fully expect Glaxo to bounce back sooner rather than later.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black man looking at phone while on the London Overground
Value Shares

After a 16% drop, FTSE 100 stock JD Sports Fashion looks like a steal to me

This FTSE 100 stock has tanked since mid-September. Edward Sheldon believes that there's value on offer after the share price…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Is now the time to buy BP shares? Here’s what the charts say

The best time to buy shares in a company is when they’re trading at a discount. But the future is…

Read more »

Investing Articles

Here’s how I’d use £50K to aim for a million when the stock market crashes

Seeing a stock market crash as a buying opportunity could prove lucrative for a well-prepared, long-term investor. Christopher Ruane explains…

Read more »

Stack of one pound coins falling over
Investing Articles

It’s up 27% with a P/E of 9! I’m considering the potential of this blossoming penny stock

Despite several years of losses, this UK penny stock has an impressive valuation. I’m looking to see if it could…

Read more »

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »